John M. Goldman

Q: What Schools Are Affiliated With John M. Goldman

John M. Goldman is affiliated with the following schools: Weizmann Institute of Science, Imperial College London, Royal Postgraduate Medical School, University of Birmingham, University of Adelaide, University of Southampton

John M. Goldman's AcademicInfluence.com Rankings

John M. Goldman

Philosophy

#3280

World Rank

#5334

Historical Rank

Logic

#1058

World Rank

#1687

Historical Rank

philosophy Degrees

John M. Goldman

Biology

#4046

World Rank

#6093

Historical Rank

Biochemistry

#405

World Rank

#483

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

John M. Goldman's Degrees

Doctorate Medicine Harvard University
PhD Biochemistry Stanford University

Why Is John M. Goldman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John M. Goldman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. (2003) (3476)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006) (3337)
Graft-versus-leukemia reactions after bone marrow transplantation. (1990) (2764)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (2002) (2065)
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. (1995) (2031)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) (1736)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2006) (1300)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. (2003) (1294)
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009) (1255)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (2002) (1196)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. (2006) (1186)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. (2002) (1068)
Chronic myeloid leukemia--advances in biology and new approaches to treatment. (2003) (959)
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. (2013) (878)
Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. (1988) (875)
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (2010) (841)
T-cell depletion of HLA-identical transplants in leukemia. (1991) (787)
International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (2009) (659)
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. (2002) (574)
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. (2008) (572)
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. (2003) (555)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (2013) (548)
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). (2000) (537)
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. (2002) (535)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (2010) (516)
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers (2005) (504)
Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia (1987) (479)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). (2010) (463)
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. (1997) (463)
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. (2012) (459)
Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. (2000) (425)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia (2009) (422)
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. (1999) (414)
Bone marrow transplantation for patients with chronic myeloid leukemia. (1986) (407)
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. (2003) (400)
Chronic myeloid leukemia: mechanisms of blastic transformation. (2010) (391)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. (2008) (391)
Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. (1994) (371)
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. (2008) (348)
Regulation of myeloid leukemia by the cell fate determinant Musashi (2010) (318)
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. (2010) (309)
Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. (2001) (301)
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (1998) (299)
Identical-Twin Bone Marrow Transplants for Leukemia (1994) (294)
1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells. (1983) (286)
An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. (1994) (283)
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998 (1998) (272)
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. (2002) (260)
A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. (1998) (260)
Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period (1997) (251)
ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA (1984) (239)
p53 in chronic myelogenous leukemia in acute phase. (1991) (235)
Chronic myeloid leukemia: current treatment options. (2001) (228)
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. (2008) (223)
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia (2006) (209)
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. (2001) (206)
How I treat chronic myeloid leukemia in the imatinib era. (2007) (204)
Chronic myelogenous leukemia: biology and therapy. (1993) (203)
Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. (1995) (203)
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. (2005) (199)
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. (1996) (198)
Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. (1992) (197)
Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effect (1988) (194)
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. (2013) (193)
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. (2008) (192)
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia (2000) (191)
The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. (1991) (188)
Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. (1996) (183)
Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia Using Sibling and Volunteer Unrelated Donors: A Comparison of Complications in the First 2 Years (1993) (180)
SEPTICAEMIA CAUSED BY VIRIDANS STREPTOCOCCI IN NEUTROPENIC PATIENTS WITH LEUKAEMIA (1983) (179)
Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission (2000) (178)
Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. (1989) (170)
Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. (1998) (168)
Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myeloma (2003) (167)
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. (2007) (161)
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. (2000) (161)
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. (2001) (161)
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. (1996) (159)
Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. (1986) (158)
Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft‐versus‐host disease and relapse (1993) (157)
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. (2000) (156)
Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation (1986) (156)
Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. (2006) (155)
Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. (1999) (154)
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia (2000) (153)
The ABL-BCR Fusion Gene Is Expressed in Chronic Myeloid Leukemia (1993) (152)
Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. (2010) (152)
POLYMERASE CHAIN REACTION FOR DETECTION OF RESIDUAL LEUKAEMIA (1989) (148)
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. (2005) (144)
A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. (1995) (142)
Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation (1993) (136)
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia (2010) (135)
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune‐mediated pathogenesis (2008) (135)
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. (2012) (133)
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. (1999) (133)
MARROW TRANSPLANTATION FOR PATIENTS IN THE CHRONIC PHASE OF CHRONIC GRANULOCYTIC LEUKAEMIA (1982) (132)
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. (2012) (131)
Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). (2000) (131)
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. (2006) (130)
Chronic myeloid leukemia: a historical perspective. (2010) (129)
Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia. (1999) (128)
Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host (2011) (125)
LATE‐ONSET HEMORRHAGIC CYSTITIS ASSOCIATED WITH URINARY EXCRETION OF POLYOMA VIRUSES AFTER BONE MARROW TRANSPLANTATION (1987) (125)
GRANULOCYTE TRANSFUSIONS IN TREATMENT OF INFECTIONS IN PATIENTS WITH ACUTE LEUKÆMIA AND APLASTIC ANÆMIA (1975) (124)
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells (2007) (124)
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. (2013) (122)
Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). (1999) (121)
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. (2010) (119)
A CHRONIC PULMONARY SYNDROME ASSOCIATED WITH GRAFT‐VERSUS-HOST DISEASE AFTER ALLOGENEIC MARROW TRANSPLANTATION (1992) (119)
Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. (1998) (118)
Mutation detection and typing of polymorphic loci through double-strand conformation analysis (1998) (118)
Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation (1997) (118)
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. (2009) (116)
Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase (1993) (115)
Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders (1984) (114)
Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. (2002) (113)
Three decades of transplantation for chronic myeloid leukemia: what have we learned? (2011) (112)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia : an analysis from the International Randomized Study of Interferon and STI 571 ( IRIS ) * (2010) (111)
Cytomegalovirus seropositivity adversely influences outcome after T‐depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft‐versus‐host disease prophylaxis (2001) (111)
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. (2003) (109)
Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? (2006) (109)
Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. (1995) (108)
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse (2005) (107)
Rearrangement of the bcr gene in Philadelphia-chromosome-negative chronic myeloid leukemia. (1986) (106)
Quality of life in long-term survivors of marrow transplantation: comparison with a matched group receiving maintenance chemotherapy. (1996) (105)
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. (2003) (104)
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. (2013) (104)
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. (2007) (104)
The International Bone Marrow Transplant Registry (2002) (104)
Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase. (1988) (103)
Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. (1991) (103)
Symptom distress, coping style and biological variables as predictors of survival after bone marrow transplantation. (1997) (103)
Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. (1993) (103)
Identification of four new translocations involving FGFR1 in myeloid disorders (2001) (98)
Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival for some patients (1984) (98)
TEL‐AML1 fusion in acute lymphoblastic leukaemia of adults (1996) (96)
Factors influencing the outcome of bone marrow transplants using unrelated donors (1997) (96)
Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. (2001) (95)
Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukaemia in transformation. (1979) (95)
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. (2013) (95)
In vitro Colony Forming Cells and Colony Stimulating Factor in Chronic Granulocytic Leukaemia (1974) (95)
Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. (1990) (94)
T-lymphoblastic Leukaemia: A Distinct Variant of Acute Leukaemia (1974) (94)
High resolution HLA class I typing by reference strand mediated conformation analysis (RSCA). (1998) (93)
Tartrate‐resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma (2003) (92)
Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells (2002) (90)
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. (2008) (90)
GENOMIC ALTERATIONS INVOLVING THE C-MYC PROTO-ONCOGENE LOCUS DURING THE EVOLUTION OF A CASE OF CHRONIC GRANULOCYTIC LEUKAEMIA (1984) (90)
4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. (1985) (89)
Prolymphocytic Leukaemia (1974) (89)
Airways obstruction associated with graft versus host disease after bone marrow transplantation. (1984) (88)
T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. (1993) (87)
Diverging effects of HLA–DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles (2010) (87)
The association of age with the presentation and outcome of tuberculosis: a five-year survey. (1993) (86)
Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis (1989) (86)
Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams. (1994) (85)
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. (2013) (85)
The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation (1997) (84)
CO-TRIMOXAZOLE FOR PREVENTION OF INFECTION IN ACUTE LEUKÆMIA (1978) (84)
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. (2000) (83)
Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. (2004) (82)
Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. (1995) (82)
Chronic Granulocytic Leukaemia: Effect of Elective Splenectomy on the Course of Disease (1975) (81)
Transfusion of circulating stem cells. (1984) (81)
Cytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia (2002) (81)
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. (2002) (80)
Molecular Epidemiology of Two Consecutive Outbreaks of Parainfluenza 3 in a Bone Marrow Transplant Unit (1998) (80)
Chemotherapy versus transplants for acute myelogenous leukemia in second remission. (1996) (80)
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. (2002) (80)
Circulating Granulocytic and Erythroid Progenitor Cells in Chronic Granulocytic Leukaemia (1980) (79)
Autografting for patients with CML in chronic phase: an update (1994) (79)
Factors influencing the false positive and negative rates of BCR‐ABL fluorescence in situ hybridization (1997) (78)
The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia (2000) (78)
Future perspectives (2010) (78)
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. (2003) (78)
Proposals for standardized reporting of results of bone marrow transplantation for leukaemia. (1989) (77)
Plasma exchange in the long-term management of Waldenström's macroglobulinemia. (1977) (77)
Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. (1991) (77)
Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. (2002) (77)
Variable numbers of BCR‐ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon‐α (1995) (76)
Unrelated Donor Bone Marrow Transplantation for Chronic Myelogenous Leukemia: A Decision Analysis (1997) (76)
Kinetics of indium-III labelled lymphocytes in normal subjects and patients with Hodgkin's disease. (1977) (76)
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. (2000) (75)
Molecular Typing Shows a High Level of HLA Class I Incompatibility in Serologically Well Matched Donor/Patient Pairs: Implications for Unrelated Bone Marrow Donor Selection (1998) (75)
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib (2005) (75)
Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans. (1996) (74)
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia (2007) (74)
Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa (2003) (73)
The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. (1998) (73)
Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review. (1993) (73)
Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be? (2009) (72)
Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. (1998) (71)
ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. (2002) (71)
Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT. (1994) (70)
Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. (2002) (69)
BCR-ABL in Chronic Myelogenous Leukemia – How Does It Work? (2008) (68)
Interferon augments PML and PML/RAR alpha expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line. (1996) (67)
False-positive results with PCR to detect leukaemia-specific transcript (1990) (67)
Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia II. STUDIES WITH MONOCLONAL ANTIBODIES AND TERMINAL TRANSFERASE (1985) (67)
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse (2001) (67)
Autotransplants in chronic myelogenous leukaemia: strategies and results (1990) (66)
Chronic Myeloid Leukemia (1997) (66)
Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. (1992) (66)
Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma (2004) (65)
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. (2010) (65)
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. (2012) (64)
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. (2009) (64)
CYTOTOXIC T LYMPHOCYTE PRECURSOR FREQUENCY ANALYSES IN BONE MARROW TRANSPLANTATION WITH VOLUNTEER UNRELATED DONORS VALUE IN DONOR SELECTION (1995) (64)
Comparison of HLA-DRB1 typing by DNA-RFLP, PCR-SSO and PCR-SSP methods and their application in providing matched unrelated donors for bone marrow transplantation. (1995) (63)
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. (2010) (63)
The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation (2003) (63)
EVIDENCE THAT UMBILICAL CORD BLOOD CONTAINS A HIGHER FREQUENCY OF HLA CLASS II‐SPECIFIC ALLOREACTIVE T CELLS THAN ADULT PERIPHERAL BLOOD (1992) (62)
BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation (2012) (62)
Acute "graft-versus-host disease" after autografting for chronic granulocytic leukemia in transformation. (1981) (62)
Diagnosis and Treatment of Chronic Myeloid Leukemia (2013) (62)
ADULT RESPIRATORY DISTRESS SYNDROME AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION: EVIDENCE FOR A NEUTROPHIL-INDEPENDENT MECHANISM (1985) (60)
DO ONCOGENES DETERMINE CLINICAL FEATURES IN CHRONIC MYELOID LEUKAEMIA? (1987) (60)
European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. (2011) (60)
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin‐6 and β2‐microglobulin in multiple myeloma (2003) (60)
Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients (2003) (60)
Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13). (1999) (59)
Acute Promyelocytic Leukaemia (1974) (59)
Human cytotoxic T lymphocytes specific for Wilms’ tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients (2003) (59)
Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. (2002) (59)
The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. (1993) (59)
A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia (1994) (58)
p53 in chronic myeloid leukemia cell lines. (1992) (58)
A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial (2012) (58)
Spleen involvement at the onset of Hodgkin's disease. (1971) (58)
Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. (1994) (58)
A ROLE FOR 1,25-DIHYDROXYVITAMIN D3 IN CONTROL OF BONE-MARROW COLLAGEN DEPOSITION? (1984) (57)
Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. (1994) (57)
Serum alkaline phosphatase at the onset of Hodgkin's disease (1970) (57)
COMPARISON OF HELPER AND CYTOTOXIC ANTIRECIPIENT T CELL FREQUENCIES IN UNRELATED BONE MARROW TRANSPLANTATION (1994) (57)
Cord blood banking: ‘providing cord blood banking for a nation’ (2009) (57)
Autologous bone marrow transplants: Different indications in Europe and North America (1989) (57)
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. (2003) (57)
Chronic myeloid leukemia-still a few questions. (2004) (56)
Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era (2005) (56)
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders. Current practice in Europe in 1996 and proposals for an operational classification. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation (EBMT). (1996) (56)
Adult onset of acute myeloid leukaemia (M6) in patients with Shwachman‐Diamond syndrome (1997) (55)
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. (2002) (53)
The position of the M‐BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukaemia (1990) (53)
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis (2013) (53)
Lack of correlation between ABL‐BCR expression and response to interferon‐α in chronic myeloid leukaemia (1996) (53)
COMBINATION THERAPY FOR ADVANCED RESISTANT HODGKIN'S DISEASE (1975) (53)
Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. (1993) (53)
IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. (2004) (52)
Molecular analysis of Philadelphia positive essential thrombocythemia. (1989) (52)
Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia (2000) (51)
CONVULSIONS DUE TO HIGH-DOSE BUSULPHAN (1984) (51)
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia (2010) (51)
Initial treatment for patients with CML. (2009) (51)
Association of diabetes mellitus with gastric bezoar formation. (1987) (51)
Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia. (1993) (50)
Incidence of antibody to eb virus, herpes simplex, and cytomegalovirus in hodgkin's disease (1970) (50)
Correlation between chromosomal abnormalities and blast phenotype in the blast crisis of Ph-positive CGL. (1986) (50)
Adoptive immunotherapy following allogeneic bone marrow transplantation. (1998) (50)
Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia (1988) (50)
A special report: bone marrow transplants using volunteer donors--recommendations and requirements for a standardized practice throughout the world--1994 update. The WMDA Executive Committee. (1994) (49)
Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. (2012) (49)
The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells. (2001) (49)
Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy (2008) (49)
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy (2007) (49)
Blast crisis of chronic granulocytic leukemia with mast cell and basophilic precursors. (1985) (49)
BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment (2011) (48)
The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoiesis. (1994) (47)
Potential mechanisms of action of interferon-alpha in CML. (1993) (47)
Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results. (1996) (46)
Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission (2000) (46)
Use of minisatellite DNA probes for recognition and characterization of relapse after allogeneic bone marrow transplantation (1988) (46)
Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. (1990) (46)
Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines. (1994) (46)
Blood Stem Cell Transplantation (1998) (46)
HLA‐identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome (1992) (46)
An atypical myeloproliferative disorder with t(8;13) (p11;q12): a third case (1994) (46)
The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. (2000) (46)
Agar culture and chromosome analysis of eosinophilic leukaemia. (1975) (45)
Adult acute lymphoblastic leukaemia: a study of prognostic features and response to treatment over a ten year period. (1986) (45)
Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene (2001) (45)
Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. (2007) (45)
Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. (2000) (44)
Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia (2002) (44)
Mutation in the ATP‐binding site of BCR‐ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571 (2002) (43)
A unifying mutation in chronic myeloproliferative disorders. (2005) (43)
Quantification of PML‐RARα transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT‐PCR for the detection of minimal residual disease and induction of the leukaemia‐specific mRNA by alpha interferon (1996) (42)
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. (2003) (42)
Summary curves for patients transplanted for chronic myeloid leukaemia salvaged by a donor lymphocyte infusion: the current leukaemia‐free survival curve (2000) (42)
Estimation of current leukaemia-free survival following donor lymphocyte infusion therapy for patients with leukaemia who relapse after allografting: application of a multistate model. (2000) (42)
Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. (2010) (41)
Rarity of microsatellite alterations in acute myeloid leukaemia. (1996) (41)
EFFECT OF SPLENECTOMY BEFORE BONE-MARROW TRANSPLANTATION ON SURVIVAL IN CHRONIC GRANULOCYTIC LEUKAEMIA (1985) (40)
Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia (2011) (40)
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. (2007) (40)
CO-TRIMOXAZOLE ALONE FOR PREVENTION OF BACTERIAL INFECTION IN PATIENTS WITH ACUTE LEUKAEMIA (1982) (40)
Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. (1996) (40)
Aplastic anemia associated with antithyroid drugs. (1991) (39)
Fatal cardiac arrest during continuous ambulatory monitoring. (1981) (39)
Serum C-reactive protein levels in the management of infection in acute leukaemia. (1984) (39)
Technical aspects and clinical applications of measuring BCR‐ABL1 transcripts number in chronic myeloid leukemia (2009) (39)
Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. (1984) (39)
Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia. (1993) (38)
A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation (2000) (38)
Production of colony-stimulating factor by leukemic leukocytes. (1976) (38)
A Novel Fusion Between MOZand the Nuclear Receptor Coactivator TIF2in Acute Myeloid Leukemia (1998) (37)
Rapid progress in chronic myelogenous leukemia. (1988) (37)
Treatment strategies for CML. (2009) (37)
Unrelated donor marrow transplantation between 1977 and 1987 at four centers in the United Kingdom. (1990) (37)
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia (2013) (37)
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. (2003) (37)
What does MRD in leukemia really mean? (2014) (37)
Psychological adaptation and symptom distress in bone marrow transplant recipients (1996) (37)
Megakaryoblastic transformation of myelofibrosis with expression of the c-sis oncogene. (2009) (37)
The use of granulocyte–colony‐stimulating factor in volunteer unrelated hemopoietic stem cell donors (2008) (36)
PROGNOSTIC FACTORS FOR OUTCOMES IN ALLOGENEIC TRANSPLANTATION FOR ADVANCED PHASES OF CHRONIC MYELOID LEUKEMIA IN THE IMATINIB ERA: A CIBMTR ANALYSIS (2011) (36)
Pulmonary function after bone marrow transplantation for chronic myeloid leukaemia. (1988) (36)
Separation of human blast progenitors from granulocytic, erythroid, megakaryocytic, and mixed colony-forming cells by "panning" on cultured marrow-derived stromal layers. (1985) (35)
Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. (2004) (35)
Donor lymphocyte infusions. (1999) (35)
Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38) (2010) (35)
Successful pregnancy after allogeneic bone marrow transplantation for chronic myeloid leukaemia (1994) (35)
Chromosomal breakage analysis in dyskeratosis congenita peripheral blood lymphocytes (1998) (35)
BCR-ABL antisense purging in chronic myeloid leukaemia (1993) (35)
Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy (2012) (35)
REVERSAL OF BLAST-CELL CRISIS IN C.G.L. BY TRANSFUSION OF STORED AUTOLOGOUS BUFFY-COAT CELLS (1978) (34)
Two cases of inv(8)(p11q13) in AML with erythrophagocytosis: a new cytogenetic variant (1998) (34)
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa (2003) (34)
Clinical decisions for chronic myeloid leukemia in the imatinib era. (2003) (34)
Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (2000) (34)
Intensive leukapheresis as initial therapy for chronic granulocytic leukemia. (1975) (34)
The effect of vitamin D3 metabolites on normal and leukemic bone marrow cells in vitro. (1984) (33)
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. (2010) (33)
OPTIONS FOR THERAPY IN CHRONIC MYELOID LEUKAEMIA (1995) (33)
Bone marrow fibre content in acute myeloid leukaemia before and after treatment. (1984) (32)
Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. (2000) (32)
Ceftazidime as first-line therapy for fever in acute leukaemia. (1985) (32)
Organ‐specific contribution to circulating C7 levels by the bone marrow and liver in humans (1996) (32)
International standardisation of quantitative real-time RT-PCR for BCR-ABL. (2008) (32)
Pretransfused patients with severe aplastic anaemia exhibit high numbers of cytotoxic T lymphocyte precursors probably directed at non‐HLA antigens (1990) (31)
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues (2009) (31)
Virilization in a postmenopausal woman due to ovarian stromal hyperthecosis. (1991) (31)
Uptake and outcome of assisted reproductive techniques in long-term survivors of SCT (2012) (30)
Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study. (2005) (30)
Does a rise in the BCR‐ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? (2009) (29)
A novel method for simultaneous high resolution identification of HLA-A, HLA-B, and HLA-Cw alleles. (1996) (29)
Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. (2008) (29)
Contact-mediated inhibition of human haematopoietic progenitor cell proliferation may be conferred by stem cell antigen, CD34. (2000) (29)
Autologous transplant for CML revisited. (1993) (29)
Factors for graft‐versus‐host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose (2007) (29)
Prolonged remission maintenance in acute myeloid leukaemia. (1977) (29)
Biological importance of residual leukaemic cells after BMT for CML: does the polymerase chain reaction help? (1990) (29)
PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia (2001) (29)
Localization of the 8;13 translocation breakpoint associated with myeloproliferative disease to a 1.5 mbp region of chromosome 13 (1995) (29)
Deficiency of a phosphatidylinositol-anchored cell adhesion molecule influences haemopoietic progenitor binding to marrow stroma in chronic myeloid leukaemia. (1991) (29)
OCULAR INVOLVEMENT IN LEUKÆMIA Report of Three Cases (1977) (29)
Prolymphocytic leukaemia: cell studies and treatment by leucapheresis. (1976) (28)
The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia. (1990) (28)
Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma. (2001) (28)
The Cryopreservation of Leukaemia Cells: Morphological and Functional Changes (1976) (28)
Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML (2014) (28)
HLA‐DA monoclonal antibodies inhibit the proliferation of normal and chronic granulocytic leukaemia myeloid progenitor cell (1982) (27)
Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis (2008) (27)
Immunological reconstitution after bone marrow transplant with Campath-1 treated bone marrow. (1987) (27)
Chronic Granulocytic Leukaemia: Multiple-drug Chemotherapy for Acute Transformation (1974) (27)
Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib. (2009) (27)
T-chronic lymphocytic leukaemia presenting as primary hypogammaglobulinaemia--evidence of a proliferation of T-suppressor cells. (1982) (27)
Association between interleukin-4-producing T lymphocyte frequencies and reduced risk of graft-versus-host disease. (1998) (27)
Philadelphia‐positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia (1986) (26)
Bone marrow transplantation in chronic myelogenous leukemia. (1992) (26)
A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics. (2002) (26)
An Extrinsic Factor Controls Neutrophil Alkaline Phosphatase Synthesis in Chronic Granulocytic Leukaemia (1980) (26)
Possible harmful effects of short course granulocyte colony‐stimulating factor in normal donors (2006) (26)
Interferon-alpha alters the distribution of CFU-GM between the adherent and nonadherent compartments in long-term cultures of chronic myeloid leukemia marrow. (1991) (26)
T-cell depletion in allogeneic bone marrow transplantation: progress and problems. (1989) (26)
Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation? (2006) (25)
Engraftment of T‐cell‐depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen (2000) (25)
Hyperleucocytic retinopathy in chronic granulocytic leukaemia: the role of intensive leucapheresis (1984) (25)
Complete remission after autografting for chronic myeloid leukaemia. (1987) (25)
Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia. (1996) (25)
Fusion of ETV 6 to the Caudal-Related Homeobox Gene CDX 2 in Acute Myeloid Leukemia (1999) (24)
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. (2012) (24)
BCR‐ABL‐positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon‐α (1998) (24)
Indications for haemopoietic precursor cell transplants in Europe (1996) (24)
Severe allergic reaction with anaphylaxis to G-CSF (lenograstim) in a healthy donor (2009) (24)
Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib. (2003) (24)
Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment. (1996) (24)
T-CELL CYTOGENETICS IN CHRONIC GRANULOCYTIC LEUKAEMIA (1982) (24)
Ponatinib for chronic myeloid leukemia. (2012) (23)
Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia. (1987) (23)
BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features (2008) (23)
Chronic myelogenous leukemia. (2001) (23)
Treatment of chronic myeloid leukaemia: some topical questions. (1997) (23)
Bone marrow transplantation for chronic myelogenous leukemia (1992) (23)
Clinical decision making in chronic myeloid leukemia based on polymerase chain reaction analysis of minimal residual disease. (1999) (23)
Bone marrow transplants using volunteer donors--recommendations and requirements for a standardized practice throughout the world. The Executive Committee of the World Marrow Donor Association. (1992) (23)
The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues (2011) (23)
Haematological Reconstitution after Autografting for Chronic Granulocytic Leukaemia in Transformation: the Influence of Previous Splenectomy (1980) (23)
Chronic myeloid leukemia: current status and controversies. (2004) (23)
Use of a hypervariable minisatellite DNA probe (33.15) for evaluating engraftment two or more years after bone marrow transplantation for aplastic anaemia (1988) (23)
A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation (1999) (22)
Primitive progenitor cells in the blood of patients with chronic granulocytic leukemia. (1986) (22)
Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas (1996) (22)
Antibody to Epstein-Barr virus in American patients with carcinoma of the nasopharynx. (1971) (22)
Chronic Myeloid Leukemia : Biology and Treatment (2003) (22)
Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: Evidence for primary or secondary humoral responses depending on donor immune status (1996) (22)
Chronic myeloid leukemia in India (2013) (22)
Prolymphocytic leukaemia. (1974) (22)
Identical twin marrow transplantation for patients with leukemia and lymphoma. (1981) (22)
THIOGUANINE AS PRIMARY TREATMENT FOR CHRONIC GRANULOCYTIC LEUKÆMIA (1975) (22)
Reduction in the stearic to oleic acid ratio in leukaemic cells — A possible chemical marker of malignancy (1985) (22)
The genomic structure of ZNF198 and location of breakpoints in the t(8;13) myeloproliferative syndrome. (1999) (22)
Measurement of serum C reactive protein concentration after bone marrow transplantation for leukaemia. (1984) (21)
Phenotype and progeny of primitive adherent human hematopoietic progenitors. (1996) (21)
Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. (1988) (21)
Antigenic expression and proliferative status of multilineage myeloid progenitor cells (CFU-GEMM) in normal individuals and patients with chronic granulocytic leukaemia. (2009) (21)
Management of infection in the neutropenic patient. (1986) (21)
Standards for blood and marrow progenitor cell processing, collection and transplantation (2000) (21)
Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone. (1987) (21)
Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients. (2009) (20)
Correlation between the proportion of Philadelphia chromosome‐positive metaphase cells and levels of BCR‐ABL mRNA in chronic myeloid leukaemia (1995) (20)
Childhood tuberculosis in Leeds, 1982-90: social and ethnic factors and the role of the contact clinic in diagnosis. (1994) (20)
VALUE OF LONG-CORE BIOPSY IN DETECTION OF DISCRETE BONE-MARROW LESIONS (1979) (20)
Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia. (1996) (20)
Fractionation of whole body irradiation before bone marrow transplantation for patients with leukaemia. (1983) (20)
Dominant‐negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia (1997) (20)
Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides (1995) (20)
New approaches in chronic granulocytic leukemia--origin, prognosis, and treatment. (1982) (20)
Consistent Fusion of ZNF 198 to the Fibroblast Growth Factor Receptor-1 in the t ( 8 ; 13 ) ( p 11 ; q 12 ) Myeloproliferative Syndrome (1998) (20)
Immunoreactive calcitonin in leukaemia. (1979) (20)
Significance of residual leukaemia transcripts after bone marrow transplant for CML (1990) (20)
Lymphocytes from multi‐transfused patients exhibit cytotoxicity against autologous cells (1992) (20)
Autografting in chronic myeloidleukaemia (1994) (19)
Allografting for chronic myeloid leukemia (1997) (19)
Antibody to Herpesvirus hominis types 1 and 2 in patients with hodgkin's disease and carcinoma of the nasopharynx (1972) (19)
A new controlled-rate cooling apparatus for freezing hematopoietic cells for storage at −196 °C (1973) (19)
Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia. (1995) (19)
Application of bone marrow transplantation in chronic granulocytic leukaemia. (1983) (19)
Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation. (2000) (19)
The abnormal p53 proteins expressed in CML cell lines are non-functional. (1993) (19)
Orthotopic liver transplantation for hepatic GVHD following allogeneic BMT for chronic myeloid leukaemia. (1992) (19)
Cytological examination of the whole endobronchial brush in bronchoscopic diagnosis of lung cancer. (2002) (18)
Use of G-CSF to mobilise PBSC in normal healthy donors--an international survey. (1998) (18)
Vasculitic neuropathy in association with chronic graft-versus-host disease (1999) (18)
Optimizing treatment for chronic myeloid leukemia. (1997) (18)
Bone marrow transplantation for patients with chronic myeloid leukaemia. (1988) (18)
Improved results with PCR for chronic myeloid leukaemia (1990) (18)
What challenges remain in chronic myeloid leukemia research? (2013) (18)
Tuberculosis and poverty. (1993) (18)
Five Year Follow-Up Results of a Phase II Trial in Patients with Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Treated with Imatinib Who Are Refractory/Intolerant of Interferon-α. (2005) (17)
Laparotomy for staging of Hodgkin's disease. (1971) (17)
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed (2011) (17)
Management of chronic myeloid leukaemia. (1994) (17)
Granulocyte-committed progenitor cells in the blood of patients with myelosclerosis. (2009) (17)
Co-ordinate expression of BI.3C5 and HLA-DR antigens on haemopoietic progenitors from chronic myeloid leukaemia. (1986) (16)
Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial (2012) (16)
High‐dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single‐centre experience (2000) (16)
Effects of cyclosporin A on human granulopoiesis in vitro. (1980) (16)
Detection of the hybrid BCR/ABL messenger RNA in single CFU-GM colonies using the polymerase chain reaction. (1990) (16)
Trimethoprim-sulfamethoxazole and hyponatremia. (1985) (16)
Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. (2007) (16)
Allogeneic stem cell transplantation for chronic myeloid leukemia–status in 2007 (2008) (16)
Chronic myelogenous leukemia--the unfolding saga. (1990) (16)
Increased Haemopoietic Cell Survival in Vitro Induced by a Human Marrow Fibroblast Factor (1981) (15)
HLA-DR monoclonal antibodies inhibit the proliferation of normal and chronic granulocytic leukaemia myeloid progenitor cells. (1982) (15)
Long-term outcome after allogeneic hematopoietic cell transplantation (HCT) for CML (2006) (15)
Evidence for a mechanism that can provide both short-term and long-term haemopoietic repopulation by a seemingly uniform population of primitive human haemopoietic precursor cells. (1995) (15)
Autografting for chronic granulocytic leukemia. (1981) (15)
Autografting cryopreserved buffy coat cells for chronic granulocytic leukaemia in transformation. (1979) (15)
Understanding Leukemias, Lymphomas and Myelomas (2005) (15)
Management decisions in chronic myeloid leukemia. (2003) (15)
Grand Rounds - Hammersmith Hospital: Clinicopathological conference Dizziness and confusion after bone marrow transplantation (1994) (15)
Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. (2002) (15)
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia. (2007) (15)
The sensitivity to hyperthermia of human granulocyte/macrophage progenitor cells (CFU-GM) derived from blood or marrow of normal subjects and patients with chronic granulocytic leukaemia. (1984) (15)
CHEMOTHERAPY FOR ADVANCED RESISTANT HODGKIN'S DISEASE (1981) (14)
Spatial and functional relationships between human hemopoietic and marrow stromal cells in vitro. (1983) (14)
MITOZANTRONE AND HIGH-DOSE CYTARABINE IN ADULT ACUTE MYELOID LEUKAEMIA (1985) (14)
Management of chronic myeloid leukaemia (1986) (14)
CD4(+) bias in T cells cloned from a CML patient with active graft versus leukemia effect. (2002) (14)
Non‐random involvement of chromosome 13 in patients with persistent or relapsed disease after bone‐marrow transplantation for chronic myeloid leukemia (2000) (14)
Production of Colony Stimulating Activity in Mixed Mononuclear Cell Culture (1980) (14)
Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells. (1998) (14)
Rearrangement of the Breakpoint Cluster Region and Expression of P210 BCR-ABL in a "Masked" Philadelphia Chromosome-Positive Acute Myeloid Leukemia (1988) (14)
Prolongation of survival in Hodgkin's disease (1971) (14)
Purification of haemopoietic progenitor cells from patients with chronic granulocytic leukaemia using Percoll density gradients and elutriation (1986) (14)
Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial (2012) (14)
The effect of 1,25-dihydroxyvitamin D3 on the relationship between growth and differentiation in HL-60 cells. (1987) (14)
ABC of clinical haematology: Chronic myeloid leukaemia (1997) (14)
Orthotopic cardiac transplantation for dilated cardiomyopathy after allogeneic bone marrow transplantation. (1994) (14)
Measurement of cytotoxic T lymphocyte precursor frequencies reveals cryptic HLA class I mismatches in the context of unrelated donor bone marrow transplantation. (1997) (13)
MAINTENANCE AND CONSOLIDATION THERAPY IN AML (1984) (13)
Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial (2013) (13)
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib (2009) (13)
The susceptibility of Philadelphia chromosome positive cells to FAS‐mediated apoptosis is not linked to the tyrosine kinase activity of BCR‐ABL (1998) (13)
Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. (2004) (13)
PREGNANCY AFTER CHEMOTHERAPY FOR HODGKIN'S DISEASE (1979) (13)
Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase. (2003) (13)
The post‐transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase (2002) (13)
CLINICAL MEASUREMENT OF SERUM C‐REACTIVE PROTEIN IN THE MONITORING AND DIFFERENTIAL DIAGNOSIS OF INFLAMMATORY DISEASES AND TISSUE NECROSIS AND IN THE RECOGNITION AND MANAGEMENT OF INTERCURRENT INFECTION (1982) (13)
CML clonal evolution with resistance to single agent imatinib therapy. (2005) (13)
Overexpression of EVI-1 in blast crisis of chronic myeloid leukemia. (1996) (13)
Bone marrow transplantation for chronic myeloid leukaemia (1987) (13)
Bone marrow transplantation for chronic myeloid leukaemia using matched unrelated donors. (1989) (13)
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era. (2006) (13)
The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies (2011) (13)
Standards for specialist units undertaking blood and marrow stem cell transplants--recommendations from the EBMT. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation (EBMT). (1995) (13)
Parasternal chest wall involvement in Hodgkin's disease. (1971) (13)
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985. (1987) (13)
A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia (2008) (13)
Antigenic characteristics of circulating CFU-GM in chronic granulocytic leukaemia resemble those of CFU-GM in normal marrow and differ from those in normal blood. (1985) (13)
Quantitation of mafosfamide-resistant pre-colony-forming units in allogeneic bone marrow transplantation: relationship with rate of engraftment and evidence for long-lasting reduction in stem cell numbers. (1996) (13)
Adhesive defects in chronic myeloid leukemia. (1989) (13)
Advances in CML. (2007) (13)
Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex‐mismatched BMT: recovery of donor‐type haemopoiesis predicted by non‐isotopic in situ hybridization (ISH) (1994) (13)
Chronic myeloid leukemia--past, present, and future. (2003) (13)
Chronic myeloid leukaemia (1997) (13)
Combination chemotherapy for stage IV Hodgkin's disease (Report no 14). (1981) (12)
The spleen in myeloproliferative disorders. (1983) (12)
Autografting in chronic granulocytic leukaemia. (1986) (12)
Mechanisms of viral leukaemogenesis. (1984) (12)
Is imatinib still an acceptable first-line treatment for CML in chronic phase? (2012) (12)
Lack of imprinting of the ABL gene (1994) (12)
World Marrow Donor Association: a progress report. (1994) (12)
MONOCLONAL ANTIBODIES REACTING WITH MYELOID CELLS (1985) (12)
Retroviral transduction of Philadelphia-positive chronic myeloid leukemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation. (1994) (12)
Autografting for patients with chronic myeloid leukemia—the hammersmith experience (1993) (12)
Immunological characterization of the tumor‐specific bcr/abl junction of philadelphia chromosome positive chronic myeloid leukemia (1993) (12)
Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy. (2012) (12)
Modern approaches to the management of chronic granulocytic leukemia. (1978) (12)
Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukaemia who relapse following bone marrow transplantation (1991) (12)
Splenectomy for histiocytic medullary reticulosis. (1971) (12)
1054PDNIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB (ERL) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (11)
Myeloproliferative disorder associated with 8p11 translocations [letter; comment] (1995) (11)
The BCR-ABLT 315 I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors , in a matched pair analysis (2013) (11)
Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons (2003) (11)
Duplex quantitative PCR for molecular monitoring of BCR‐ABL1‐associated hematological malignancies (2011) (11)
Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial (2013) (11)
Relationship of the duration of the chronic phase in chronic granulocytic leukaemia to the need for treatment during the first year after diagnosis (2004) (11)
Interleukin 3 (IL-3), but not stem cell factor (SCF) increases self-renewal by human erythroid burst-forming units (BFU-E) in vitro. (1998) (11)
BCR‐ABL‐positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions (1996) (11)
Increased eosinophil colony formation in agar by haemopoietic cells from patients with the hypereosinophilic syndrome. (1981) (11)
Etiologic study of nasopharyngeal cancer. (1971) (11)
Analysis of Rejection in HLA Matched T-Depleted Bone Marrow Transplants (1985) (11)
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. (2012) (11)
Antisense therapy for malignant disease (1994) (11)
Screening of patients with retinitis pigmentosa for heredopathia atactica polyneuritiformis (Refsum's disease). (1985) (11)
[The 8p11 myeloproliferative syndrome]. (1999) (11)
Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo. (2001) (10)
HIV infection due to a platelet transfusion after allogeneic bone marrow transplantation (1987) (10)
Chronic myeloid leukemia stem cells: now on the run. (2009) (10)
Ocular involvement in leukaemia. Report of three cases. (1977) (10)
Options for the Management of Chronic Myeloid Leukaemia-1990. (1990) (10)
GENERAL ANÆSTHESIA FOR HIGH-DOSE TOTAL-BODY IRRADIATION (1978) (10)
BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML. (2009) (10)
Percutaneous retrieval of catheter fragments from heart and great vessels: five cases. (1983) (10)
[History of chronic myeloid leukemia: a paradigm in the treatment of cancer]. (2014) (10)
Quantitative molecular methods to monitor the response of CML patients to interferon-alpha. (1996) (10)
Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT (2013) (10)
Urban deprivation and tuberculosis in the elderly. (1994) (10)
CLINICAL APPLICATIONS OF BONE-MARROW CULTURE (1975) (10)
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop (2013) (10)
NEW COMBINATION CHEMOTHERAPY FOR RELAPSED ACUTE MYELOID LEUKAEMIA (1984) (10)
Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients? (2005) (9)
Chronic myeloid leukaemia: a therapeutic challenge. (1995) (9)
Chronic Myeloid Leukemia — A Brief History (2007) (9)
Induction of a syngeneic graft-versus-leukemia effect following bone marrow transplantation for chronic myeloid leukemia. (1990) (9)
Wegener's granulomatosis involving prostate. (2005) (9)
Effect of platelet-derived growth factor on enriched populations of haemopoietic progenitors from patients with chronic myeloid leukaemia. (1987) (9)
Dual inhibition of ras and bcr‐abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission (2007) (9)
Autologous/syngeneic stem cell transplantation to treat refractory GvHD (2004) (9)
Cimetidine and cardiac dysrhythmias. (1982) (9)
Meningoencephalitis associated with Chlamydia trachomatis infection. (1983) (9)
ACYCLOGUANOSINE FOR VIRAL PNEUMONIA (1979) (9)
Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial (2012) (9)
Increased T-lymphocyte numbers in chronic granulocytic leukemia before treatment. (1984) (9)
Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival (2008) (9)
Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy. (2005) (9)
Busulfan alone as cytoreduction before autografting for chronic myelogenous leukemia. (1998) (8)
Increased DR antigen expression by committed hemopoietic progenitor cells but not primitive progenitor cells in chronic myeloid leukemia. (1988) (8)
Matched unrelated donor transplantation. (1989) (8)
Treatment of chronic myeloid leukaemia lessons and challenges (2002) (8)
Implications of imatinib mesylate for hematopoietic stem cell transplantation. (2001) (8)
Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007. (2007) (8)
Autografting in chronic myeloid leukaemia. (1994) (8)
Chronic myeloid leukemia: reversing the chronic phase. (2010) (8)
Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib (2011) (8)
Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele. (2006) (8)
The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy (2011) (8)
Immunoreactive calcitonin production by a human promyelocytic leukemia cell line HL60. (1983) (8)
The Use of Dasatinib in Chronic Myeloid Leukemia: Some Practical Considerations (2007) (8)
Restoration of sensitivity to STI 571 in STI 571-resistant chronic myeloid leukemia cells (2001) (8)
Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system (2012) (8)
Chronic myeloid leukemia: the basis of treatment for tomorrow (2011) (8)
Treating Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors (2013) (8)
Characterization of a t(10;12)(q24;p13) in a case of CML in transformation (1997) (8)
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms (2014) (8)
Antigenic determinants on myeloid leukaemia colony‐forming cells resemble those of normal myeloid progenitor cells and differ from those of circulating blast cells (1986) (7)
Myeloproliferative and myelodysplastic syndromes: the future. (2003) (7)
Rearrangement of the breakpoint cluster region and expression of P210 BCR-ABL in a "masked" Philadelphia chromosome-positive acute myeloid leukemia. (1988) (7)
The next questions in chronic myeloid leukaemia and their answers. (2013) (7)
THE PHILADELPHIA CHROMOSOME: FROM CYTOGENETICS TO ONCOGENES (1987) (7)
Impact of Baseline Mutations on Response to Ponatinib and End of Treatment Mutation Analysis in Patients With Chronic Myeloid Leukemia (2014) (7)
BONE MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA (1986) (7)
Interferon-a Overrides the Deficient Adhesion of Chronic Myeloid Leukemia Primitive Progenitor Cells to Bone Marrow Stromal Cells (2003) (7)
Bone marrow transplantation for CML. (1987) (7)
Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization. (2000) (7)
Stem cell transplantation for chronic myeloid leukaemia: the role of infused marrow cell dose. (2001) (7)
BONE-MARROW CULTURE IN ACUTE MYELOID LEUKÆMIA (1976) (7)
Viral (polyomavirus) cystitis heralding cytomegalovirus infection (1992) (7)
Alkaline phosphatase activity of chronic granulocytic leukaemia neutrophils in agar culture. (2009) (7)
Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia (2015) (7)
Prospects for cure in leukaemia. (1987) (7)
The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors. (2008) (7)
Alloreactive cytotoxic T-cell frequency analysis and HLA matching for bone marrow transplants from HLA matched unrelated donors. (1989) (7)
Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial (2012) (7)
Use of autotransplants in chronic myeloid leukaemia. (1992) (6)
The bcr gene is joined to c-abl in Ph1 chromosome negative chronic myelogenous leukemia. (1988) (6)
Molecular biology and treatment of chronic myelogenous leukemia. (1990) (6)
A case of myelofibrosis with a t(4;13)(q25;q12): evidence for involvement of a second 13q12 locus in chronic myeloproliferative disorders (1999) (6)
Cytotoxic T lymphocyte precursor (CTL-p) frequency analysis in unrelated donor bone marrow transplantation: two case studies. (1991) (6)
Buffy coat autografts for patients with chronic granulocytic leukaemia in transformation (1981) (6)
Bone Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic Phase (2020) (6)
Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia. (2013) (6)
Interaction of CyA and Ketoconazole (1983) (6)
Minor antigen solves major problem (2001) (6)
Helper T-lymphocyte precursor frequencies predict risks of graft-versus-host disease in bone marrow transplantation. (1993) (6)
Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome. (2004) (6)
A Nordic registry for volunteer marrow donors? (1990) (6)
Similarity of p53 expression by CD34+ cells in chronic myeloid leukemia and normal progenitors detected by flow cytometry. (1992) (6)
Treatment of chronic granulocytic leukaemia with repeated single doses of busulphan. (1979) (6)
Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) (2013) (6)
Bone Marrow Transplantation for Patients in the Chronic Phase of Chronic Granulocytic Leukaemia: Apparent Low Incidence of Relapse within the First Two Years Post-BMT (1985) (5)
Intermediate‐dose busulphan before autografting for advanced‐phase chronic myeloid leukaemia (1996) (5)
NGS-Assisted DNA-Based Digital qPCR Facilitates Stratification Of CML Patients In Long-Term Molecular Remission Based On The Presence Of Detectable BCR-ABL1 DNA (2013) (5)
Validation of the International Scale for Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors. (2007) (5)
Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment. (2006) (5)
Care of bone marrow donors (1993) (5)
Endogenous erythroid colony formation in myeloproliferative diseases does not depend on T cells. (1986) (5)
Studies on cellular interactions between stromal and haemopoietic stem cells in normal and leukaemic bone marrows. (1984) (5)
Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects (2014) (5)
Haemolysis after granulocyte transfusions. (1980) (5)
Management of chronic myeloid leukaemia in lymphoid blast transformation. (1993) (5)
Molecular investigation of secondary chronic myeloid leukemia. (1996) (5)
BCR-ABL transcripts are not detected in cord blood or the peripheral blood of the newborn child whose mother developed chronic myeloid leukemia while pregnant. (2010) (5)
An outbreak of tuberculosis in the South West of England related to a public house. (2005) (5)
Antigen Society no. 114: HLA-C. (1992) (5)
Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy (1997) (5)
SPLENECTOMY FOR COMPLICATIONS OF CHRONIC GRANULOCYTIC LEUKÆMIA (1975) (5)
Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) (2013) (5)
Proliferation in liquid culture of megakaryocytes from the blood of patients with primary myelofibrosis and other myeloproliferative disorders. (1985) (5)
Atypical promyelocytic leukemia (M3) with immature primary granules and t(15;17). (1985) (5)
Generalised allergy to porcine and bovine monocomponent insulins. (1980) (5)
Pleural Effusions Associated with Use of Dasatinib in Chronic Myeloid Leukemia May Have an Auto-Immune Pathogenesis. (2007) (5)
Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs) (2013) (5)
Posterior leucoencephalopathy syndrome (1996) (4)
Microsatellite instability in myeloid leukemias. (1994) (4)
Allogeneic bone marrow transplantation: state of the art and future directions. (1989) (4)
Individual variation in alloresponsiveness and the molecular basis of allorecognition. (1990) (4)
First Results from a Collaborative Initiative To Develop an International Scale for the Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors. (2006) (4)
Persistence of BCR/ABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse. (1991) (4)
A new HLA Cw6 split -Cw6.2- detected in three ethnic groups that is inherited in families. (1993) (4)
The Kingscord model: a public cord blood collection service (2009) (4)
Comparisons of the composition of fat cells obtained from the marrow of normal individuals or of subjects with aplastic anemia and from bone marrow cultures. (1984) (4)
Recurrent bone marrow necrosis and extramedullary myeloid deposits in Philadelphia negative chronic myeloid leukaemia. (1988) (4)
Conference reportThe Third International Congress on Myeloproliferative and Myelodysplastic Syndromes (2007) (4)
Chronic granulocytic leukemia--selective removal of immature granulocytic cells by leukapheresis. (1975) (4)
Immunotherapy for chronic myeloid leukaemia. (1998) (4)
Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group. (2002) (4)
Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London – 2005 (2006) (4)
Not so NICE for CML (2002) (4)
Direct Adoptive Transfer of Cytomegalovirus-Specific CTL from Unrelated Donors to Stem Cell Transplant Patients Following Selection by HLA-Peptide Tetramers. (2004) (4)
Donor lymphocyte infusions (dli) for cml: Factors influencing the effective cell dose and implications for the definition of refractoriness (2000) (4)
The significance of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. (2013) (4)
Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction. (1997) (4)
Myeloproliferative disorder associated with 8p11 translocations. (1995) (4)
Graft vs. leukaemia reactions in chronic myeloid leukaemia. (1992) (4)
The influence of INK 4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells (2001) (3)
Hematopoietic Stem Cells and Primitive Progenitors Express Leukemia-Associated Antigens That May Be Targets for Graft-Versus-Leukemia Effect or for Vaccine-Based Immunotherapy in Chronic Myeloid Leukemia. (2006) (3)
Tuberculosis and Urban Deprivation in the Elderly (1994) (3)
CML yields a few more clues (2002) (3)
The use of plastic isolators to prevent infection in neutropenic patients (1976) (3)
Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution. (2007) (3)
Biology of CML stem cells: the basis for clinical heterogeneity? (2012) (3)
Myeloid Leukemia of Multiple Genes Implicated in the Pathogenesis of Chronic Tyrosine Kinase Activity Regulates the Expression BCR-ABL Updated (2000) (3)
Residual Ph‐negative stem cells in chronic myeloid leukemia‐sometimes or always? (1993) (3)
COMPARISON OF GRAFT-VS-HOST-DISEASE AND SURVIVAL AFTER HLA- IDENTICAL SIBLING BONE MARROW TRANSPLANTATION IN DIFFERENT ETHNIC POPULATIONS Running Head: Graft-vs-host disease in ethnic populations For Submission to BLOOD, Clinical Observations (2004) (3)
Preservation of Hemopoietic Stem Cells (1984) (3)
SIGNIFICANCE OF SPLENOMEGALY IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKÆMIA IN REMISSION (1980) (3)
Effect of levamisole on granulopoiesis in agar culture. (1980) (3)
Microsatellite instability in myeloid leukemias [letter; comment] (1994) (3)
Vaccine Intervention Against Virus-Induced Tumours (1986) (3)
Molecular profiling of CD34+ cells identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival in CML patients (*) (2005) (3)
C-Reactive Protein on Admission Predicts Transplant-Related Mortality in Recipients of Allogeneic Stem Cell Transplant. (2007) (3)
Leucocyte separation and transfusion. (1974) (3)
Toxicities of Dextrans (1976) (3)
The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission, (2011) (3)
Detection and significance of minimal residual disease in patients with leukaemia and lymphoma. (1991) (3)
Subacute thyroiditis after bone marrow transplant for chronic granulocytic leukaemia. (1987) (3)
Proposal for a novel prognostic index ( RANKL ) / osteoprotegerin ( OPG ) ratio predicts survival in multiple (2003) (3)
The genomic breakpoint in a patient with Philadelphia-positive acute leukemia is 5' of the breakpoint cluster region. (1988) (3)
Staging of leukemic progenitor cells in acute myeloid leukemia by phenotyping with myeloid monoclonal antibodies. (1986) (3)
HISTOCOMPATIBLE UNRELATED VOLUNTEER DONORS FOR BMT IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA (1988) (3)
A new controlled-rate cooling apparatus for freezing hematopoietic cells for storage at -196 degrees C. (1973) (3)
Autografting for chronic myeloid leukaemia--palliation, cure or nothing? (1992) (3)
Autologous blood stem cell transplantation. (1988) (2)
An unfortunate case of allergy to latex (2000) (2)
Stem Cell Transplantation for Chronic Myeloid Leukaemia (1999) (2)
Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia. (2006) (2)
1,25(OH)2D3 causes monocytic differentiation of normal human bone marrow in vitro (1983) (2)
Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients (2014) (2)
Autografting for CML--where does it fit in to the overall treatment strategy? (1994) (2)
OA15.04 Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer (2021) (2)
Six Year Follow-Up Results of a Phase II Study of Imatinib in Late Chronic Phase (L-CP) Chronic Myeloid Leukemia (CML) Post Interferon-A (IFN) Refractoriness/Intolerance. (2006) (2)
1,25-DIHYDROXYVITAMIN D3 AND MYELOFIBROSIS (1984) (2)
BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID-LEUKEMIA (CML) USING MATCHED UNRELATED DONORS (1988) (2)
Philadelphia chromosome-positive acute lymphoid leukemias A phase 2 study of imatinib in patients with relapsed or refractory (2009) (2)
Management of chronic myeloid leukaemia in pregnancy (1991) (2)
A History of the Chronic Leukemias (2013) (2)
Colony-forming cells and myeloblasts in chronic granulocytic leukaemia. (1977) (2)
Classifying scientific meetings (1999) (2)
Bone-marrow transplantation for leukaemia (1995) (2)
Hematopoietic stem cell transplantation. (1998) (2)
INFUSION OF AUTOLOGOUS BUFFY COAT CELLS FOR CGL IN TRANSFORMATION (1980) (2)
Approaches to the treatment of chronic myeloid leukemia. (1994) (2)
Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement? (2012) (2)
Interactive web-based guidelines for chronic myeloid leukaemia (2004) (2)
European School of Oncology Task Force Papers: gene therapy--a future in cancer management? Antisense therapy for malignant disease. (1994) (2)
Phenotype and function of plastic-adherent progenitor cells in human hematopoietic tissue (1995) (2)
A short variant of A9 that is identical to A9V2. (1992) (2)
Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH‐296 (1999) (2)
A new impetus for The Hematology Journal. (2002) (2)
Total lymphoid irradiation preceding bone marrow transplantation for chronic myeloid leukaemia. (1989) (2)
Imatinib: A Viewpoint by John M. Goldman. (2001) (2)
BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA (1985) (2)
Allogeneic Stem Cell Transplantation: The Last Century (2010) (2)
MITOZANTRONE-INDUCED ASTEATOSIS (1985) (2)
Cost-effectiveness of interferon-α for chronic myeloid leukemia (1998) (2)
Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy. (2007) (2)
Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1st Line IM Patients. (2006) (1)
Haemopoietic stem cell autografts for leukaemia (1980) (1)
Chronic myeloid leukemia – Therapy in the 20th and 21st centuries (2007) (1)
Reply to D.L. White et al (2012) (1)
Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib (2008) (1)
Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT). (2007) (1)
General anaesthesia for high-dose total-body irradiation. (1979) (1)
Survival in chronic myelogenous leukemia. (1994) (1)
Hematopoietic stem cell transplantation: Editorial overview (1996) (1)
Myeloid Leukemia Development of Resistance to Imatinib Mesylate in Chronic Bcr-Abl Expression Levels Determine the Rate of Updated (2005) (1)
SELECTION FOR UNRELATED DONOR BONE MARROW TRANSPLANTATION (1989) (1)
Chronic myeloid leukaemia--the XXI century. (1993) (1)
Relevance of DNA heteroduplex crossmatching in the selection of bone marrow donors (1994) (1)
Genetic rearrangements in leukaemia and lymphoma (1986) (1)
Non‐lymphoid blast crisis of CML with rearrangement of immunoglobulin and T‐cell receptor delta genes (1991) (1)
Long-Term Benefits of Imatinib in Patients with Chronic Myeloid Leukemia (2006) (1)
For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance. (2007) (1)
Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia. (2009) (1)
[Host-graft interactions after allogenic bone marrow transplantation; choice of donor]. (1988) (1)
No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogeneic transplantation for chronic myeloid leukemia (2000) (1)
The third International Congress on Myeloproliferative and Myelodysplastic Syndromes. (2007) (1)
Highlights from: Third Annual Symposium on Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia; Sarasota, FL; September 8-10, 2006 (2006) (1)
Leucocytes : separation, collection, and transfusion : proceedings of the International Symposium on Leucocyte Separation and Transfusion held at the Royal Postgraduate Medical School, London on September 9th, 10th, and 11th, 1974 (1975) (1)
XVIIth International Symposium on Technological Innovations in Laboratory Hematology (2004) (1)
Biochemical studies on the defects induced in human neutrophilic polymorphonuclear leukocytes during attempted cryopreservation (1980) (1)
27. Chronic Myeloid Leukaemia (2010) (1)
Long‐term safety of filgrastim (rhG‐CSF) administration: response to Confer & Miller and Bacher & Zander (2007) (1)
P73. Regulation of myeloid leukemia by the cell fate determinant Musashi (2010) (1)
Bone marrow transplantation in Europe: major geographical differences. The European Group for Bone Marrow Transplantation [EBMT]. (1993) (1)
Chronic myeloid leukemia[mdash ]Past, present, and future (2003) (1)
CHAPTER 4 – Chronic myeloid leukemia (2009) (1)
Survival after bone-marrow transplantation (2002) (1)
An integrated approach to the management of chronic myeloid leukemia. (1996) (1)
lymphocytes specific for WT1 Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T (2013) (1)
Philadelphia chromosome-negative progenitors in chronic granulocytic leukemia. (1983) (1)
Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era. (2008) (1)
Adult acute leukaemia: prospects for cure. (1981) (1)
Bonemarrow transplantation for chronic myeloid leukaemia (1992) (1)
Effect of biofeedback on patients' tolerance of fibreoptic bronchoscopy. (1986) (1)
Leukemianet Recommendations from an expert panel on behalf of the European Evolving concepts in the management of chronic myeloid leukemia. (2011) (1)
2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection (2010) (1)
Peripheral blood stem cell autografts in CML. (1993) (1)
PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients (2012) (1)
Changes in surface antigens of HL-60 cells during differentiation in vitro (1984) (1)
Autografting for CML--overview and perspectives. (1996) (1)
Cost-effectiveness of interferon-alpha for chronic myeloid leukemia. (1998) (1)
Reduced incidence of GVHD in recipients of t-cell depleted marrow (1986) (1)
Chronic myeloproliferative disorders (2008) (1)
Soluble receptor activator of nuclear factor (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index. (2003) (1)
T-Cell Depletion with Campath 1 to Prevent GVHD (1985) (1)
A Perspective on the Molecular Evolution of Chronic Myeloid Leukemia from Chronic Phase to Blast Transformation (2006) (1)
Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis (2008) (1)
Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib? (2012) (1)
need for further investigation into the effects of discontinuing imatinib therapy in those patients who wish to conceive. (2017) (1)
[Detection of strain-specific antigens on normal myeloid stem cells and on leukemic blasts using cytotoxic monoclonal antibodies and complement]. (1985) (1)
High Levels of CD34 Expression in Bone Marrow Trephines Predicts for Loss of Cytogenetic Response in Patients with in Chronic Phase Who Have Achieved Complete Cytogenetic Remission on Imatinib Therapy. (2004) (1)
Timing of transplant for CML patients. (1984) (1)
Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations (2011) (1)
Immune therapy of chronic myelogenous leukemia. (2005) (1)
BIOLOGICAL DIFFERENCES IN THE THREE MAJOR LEUKAEMIAS (1988) (1)
Selective elimination of leukemic progenitors by allorestricted CTL specific for Wilms tumor antigen-1 (WT-1). (1999) (1)
Bone marrow transplantation in Europe—can the geographical differences be explained? (1993) (1)
RT-PCR studies in patients with chronic myeloid leukemia (CML) in remission 5 years after allogeneic stem cell transplant (SCT) define risk of subsequent relapse (2000) (1)
Pneumocystis carinii pneumonia infection in a patient with known chronic mucocutaneous candidiasis (2005) (1)
Molecular Profiling of CD34+ Cells from Diagnosis in CML Patients Identifies Low Expression of CD7 with High Expression of Proteinase 3 or Elastase as Predictors of Longer Survival. (2005) (1)
Comparison of HLA-A19 subtyping by PCR-SSP and serology (1994) (0)
Filtration leukapheresis--a reference procedure. (1979) (0)
Analysis of TCR V(beta) usage in T cell lines showing specificity for autologous leukaemic cells generated from a patient receiving DLT for relapse following BMT IA (1998) (0)
The patient and the specialist (2005) (0)
Tuberculosis in the Elderly: A Survey of Radiographic Features (1992) (0)
The use of a PCR-SSO molecular typing technique in providing confirmatory analysis of HLA class I antigens for bone marrow donor selection (1994) (0)
karyopherin inhibitor KPT-330 in Ph Preclinical and clinical efficacy of XPO 1 / CRM 1 inhibition by the (2013) (0)
Bortezomib Treatment Of Primitive Quiescent CD34+ Cell S In Chronic Myeloid Leukemia Enhances Targeting By In Vitro Expanded Allogeneic Natural Killer Cell S (2009) (0)
What to tell the employer. (1977) (0)
Highlights from the First Global Chronic Myeloid Leukemia Workshop; Bermuda; December 15–16, 2006 (2007) (0)
RESULTS OF T-CELL DEPLETION WITH CAMPATH-1 IN BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC GRANULOCYTIC-LEUKEMIA (CGL) (1985) (0)
BONE-MARROW TRANSPLANTATION USING UNRELATED DONORS FOR CML IN CHRONIC PHASE (1991) (0)
complete cytogenetic remission on imatinib Molecular monitoring in chronic myeloid leukemia patients who achieve (2013) (0)
Brief report Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy (2011) (0)
To the Editor. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia (2001) (0)
An Extrinsic Factor Controlling Neutrophil Alkaline Phosphatase in Chronic Granulocytic Leukaemia (1980) (0)
Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia (2010) (0)
Treatment options in chronic myelogenous leukemia. Authors' reply (2002) (0)
Potential treatment algorithms and future directions for patients with chronic myeloid leukemia (2008) (0)
Clinical Features of Tuberculosis in the Elderly (1992) (0)
Stem cell transplantation for leukemias, lymphomas and myelomas (2005) (0)
Comprar Cataract Surgery: FCO Series | Tariq Mughal | 9780727912015 | Wiley (2009) (0)
hematopoietic progenitor cells The influence of INK4 proteins on growth and self-renewal kinetics of (2013) (0)
Report on slide session, British Society for Haematology, 43rd Annual Scientific Meeting, Glasgow, 2003. (2004) (0)
EXPRESSION OF H-OCT1 PREDICTS FOR ACHIEVEMENT OF CCYR IN IMATINIB TREATED PATIENTS WHILE THE LEVEL OF PHOSPHO-CRKL INHIBITION IN CD34 POSITIVE CELLS SEEMS TO BE OF LITTLE PROGNOSTIC VALUE (2008) (0)
Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (2011) (0)
CHARACTERIZATION OF BLAST CELLS BY ULTRASTRUCTURAL CYTO-CHEMISTRY AND MONOCLONAL-ANTIBODIES (1983) (0)
Antigenic phenotype of leukaemic progenitor cells (AML-CFU-L) in three cases of megakaryocytic leukaemia (1986) (0)
Neurogenic bladder in Legionnaires' disease. (1986) (0)
Letter: Bone-marrow culture in acute myeloid leukaemia. (1976) (0)
Hemopoiesis and blood cells (2005) (0)
Bone marrow transplantation for chronic myeloid leukemia. (1995) (0)
Therapeutic exploitation of genetic defects in haematological malignancies. (1995) (0)
2 prior lines of TKI therapy failed patients with chronic myeloid leukemia in chronic phase who have Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in (2013) (0)
Reliability of ACTH levels in Cushing's syndrome. (1984) (0)
PR1-Specific T Cell Responses in the First Months Following T-Cell Depleted Allogeneic Stem Cell Transplantation Occur in Both Myeloid and Non-Myeloid Malignancies but Are Only Associated with a GVL Effect in Myeloid Leukemias. (2006) (0)
Treatment of leukemias, lymphomas and myelomas and clinical trials: additional considerations (2005) (0)
High resolution molecular typing to ensure allele level matching for six highly polymorphic HLA antigens increases the overall survival in volunteer donor stem cell transplantation, however 'perfect' matches are found in only 10% of pairs. (2001) (0)
Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. (2010) (0)
Imatinib or transplant for chronic myeloid leukaemia? (2003) (0)
Treatment of leukemias, lymphomas and myelomas: current practice (2005) (0)
without having achieved an optimal response myeloid leukemia who interrupt therapy on account of pregnancy Poor outcome after reintroduction of imatinib in patients with chronic (2013) (0)
What happens in leukemias, lymphomas and myelomas? (2005) (0)
Cytogenetic evolution after bone marrow transplantation for chronic myeloid leukaemia. (1988) (0)
after allogeneic stem cell transplantation Direct visualization of cytomegalovirus-specific T-cell reconstitution (2012) (0)
Comprar Understanding Leukaemia and Related Cancers | Vikas Bhushan | 9780632053469 | Wiley (2009) (0)
Comparison of HLA A19, A10 and A28 subtyping by PCR-SSP and serological techniques (1994) (0)
Cure of chronic myeloid leukeaemia (2001) (0)
New Horizons with Biological Response Modifiers in Haematological Malignancies: Satellite Symposium at the 24th Congress of the International Society of Haematology, London, August 1992 (1993) (0)
Royal Academy of Medicine — proceedings of meetings of section of pathology 1984/1985 (1986) (0)
Theuseofplastic isolators toprevent infection inneutropenic patients (1976) (0)
Advances in treatment of chronic myeloid leukaemia. (2000) (0)
Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets (2011) (0)
Adverse drug reactions in children: New perspectives on old problems (2016) (0)
Hyperleukocytic retinopathy in CGL; the role of leukapheresis (1984) (0)
Summary of treatment and recommended follow-up of CML patients (2014) (0)
Autografting for Chronic Myelogenous Leukemia: Is there a Role? (2020) (0)
P455 - Cytotoxic T lymphocyte precursor frequency (CTLp) analysis and prediction of clinical outcome following unrelated donor BMT (1996) (0)
T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors. (2009) (0)
Primitive Quiescent CD34+ Cells in Chronic Myeloid Leukemia Are Targeted by In Vitro Expanded Allogeneic Natural Killer Cells, Which Are Functionally Enhanced by Bortezomib Treatment. (2007) (0)
Monitoring CML after nonmyeloablative transplantations: how negative is negative? (2003) (0)
IL-4 gene polymorphism and outcome following sibling allogeneic bone marrow transplant (2001) (0)
myeloid leukemia: implications for early intervention strategies Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic (2013) (0)
S02 Molecular monitoring and ELN guidelines for CML (2007) (0)
Bone Marrow Transplantation Published on behalf of: The European Group for Blood and Marrow Transplantation (2003) (0)
Clearer References (1969) (0)
Bone marrow transplantation (1995) (0)
This information is current as Strains of the Virus pp65 That Are Conserved Between Eight Epitopes in the Cytomegalovirus Protein HLA-A*0201-Restricted Cytotoxic T Cell Identification of Three (2013) (0)
Points: Screening patients with retinitis pigmentosa for Refsum's disease (1985) (0)
Book Review Bone Marrow Transplantation Edited by Stephen J. Forman, Karl G. Blume, and E. Donnall Thomas. 942 pp., illustrated. Cambridge, Mass., Blackwell Science, 1994. $225. 0-86542-253-2 (1995) (0)
Comprar Chronic Myeloproliferative Disorders | John M. Goldman | 9780415415989 | Informa Healthcare (2008) (0)
The Decision to Offer Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era (2006) (0)
Current Role of Stem Cell Transplantation for Leukemias, Lymphomas, and Myelomas (2013) (0)
Subject Index Vol. 119, 2008 (2008) (0)
chronic myeloid leukemia Factors affecting duration of survival after onset of blastic transformation of (2013) (0)
KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib (2010) (0)
Where Are We Today with Imatinib Therapy (2006) (0)
Uptake and Outcome of Artificial Reproductive Techniques Following Allogeneic Stem Cell Tranplantation: A Single Centre Experience. (2009) (0)
Plasma exchange inthelong-term management ofWaldenstrom's macroglobulinemia (1977) (0)
The new era of imatinib mesylate (2004) (0)
lymphocytes specific for WT 1 progenitor cells by cytotoxic T + Selective elimination of leukemic CD 34 (2000) (0)
Adult acutelymphoblastic leukaemia: A study ofprognostic features andresponsetotreatment overa tenyearperiod (1986) (0)
How Best to Express the Results of Serial RQ-PCR Studies to Measure Minimal Residual Disease in Treated Leukaemia Patients?. (2004) (0)
Reversal of myelofibrosis in acute megakaryoblastic leukaemia following allogeneic marrow transplantation (1983) (0)
CD4 positive leukemia specific T cell clones are present during the graft-versus-leukemia response after allogeneic bone marrow transplantation for chronic myeloid leukemia (1996) (0)
Graft-versus-leukaemia (GVL) effect post allogeneic BMT is mediated by CML specific T cell clones (1996) (0)
Late relapse after allogeneic bone marrow transplantation for Philadelphia-positive acute lymphoblastic leukaemia. (1993) (0)
Commentary (Goldman)—Chronic Myeloid Leukemia: Changing the Treatment Paradigms (2017) (0)
Stem cell replacement for chronic granulocytic leukaemia. (1980) (0)
Autologous stem-cell transplantation for chronic myelogenous leukemia. (1993) (0)
High resolution HLA Class I typing by double strand conformation analysis (DSCA). (1998) (0)
Clinical aspects of chronic myeloid leukemia (2008) (0)
Response: Reliability of PCR for BCR-ABL transcripts (2007) (0)
P47.03 Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2 (2021) (0)
Bone marrow transplantation: Editorial overview (1995) (0)
Imatinib: profile report (2002) (0)
Cure of leukaemia by bone marrow transplantation (1993) (0)
expressing results transcripts and kinase domainBCR-ABLmethodology for detecting inhibitors : review and recommendations for harmonizing current Monitoring CML patients responding to treatment with tyrosine kinase (2006) (0)
Cytotoxic T Lymphocyte Responses to PR1 Peptide in Chronic Myeloid Leukemia Patients Inversely Correlate with Proteinase 3 and Elastase Expression but Donor PR1 Responses Determine Survival after Stem Cell Transplantation. (2006) (0)
Unraveling CML phase by phase (2007) (0)
The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML) (2022) (0)
newly diagnosed patients with chronic myeloid leukemia in KIR2DS1 Dasatinib may overcome the negative prognostic impact of (2013) (0)
Varying Response to Imatinib in CML Patients with BCR-ABLM244V Mutation. (2005) (0)
Different Types of Leukemias, Lymphomas, and Myelomas (2013) (0)
Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse. (2012) (0)
Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia (2008) (0)
Current treatment of chronic myelogenous leukemia. (1989) (0)
Percutaneous retrieval of embolised catheters. (1983) (0)
Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Interferon, and Allogeneic Bone Marrow Transplantation in Treating the An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, (2013) (0)
Therapeutic Strategies and Concepts of Cure in CML (2007) (0)
333: Cytotoxic T lymphocyte responses to PR1 peptide in CML patients inversely correlate with proteinase 3 and elastase expression but donor PR1-responses determine molecular remission and disease eradication after stem cell transplantation (2007) (0)
BONE-MARROW TRANSPLANTATION FOR CHRONIC PHASE CML - THE ROLE OF T-CELL DEPLETION IN 1988 (1988) (0)
Advances in the biology and therapy of chronic myeloid leukemia (CML): Proceedings from the 6 th Post-ASH International CML and Myeloproliferative Neoplasms Workshop (2013) (0)
study : Presented in part at the 43rd Annual Meeting of The American chronic myelogenous leukemia in myeloid blast crisis: results of a phase II Imatinib induces hematologic and cytogenetic responses in patients with (2013) (0)
The influence of the cytokine receptor signalling class on cord blood progenitor cell self replication kinetics (1998) (0)
Why anonymous? (1993) (0)
Recognition of pediatric Crohn's disease presenting as appendicitis (2011) (0)
A high resolution molecular typing method for the simultaneous identification of HLA class I alleles (1996) (0)
Bone marrow transplantation for chronic myeloid leukaemia. (1987) (0)
leukemia cells Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid (2013) (0)
PI3-Kinase may be involved in cml progenitor cell responses to interferon alfa and STI571 (2000) (0)
leukemia after allogeneic stem cell transplantation Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid (2013) (0)
P221 - Complementary strand analysis (CSA): A new method for isolation and identification of amplified allelic DNA fragments (1996) (0)
Risk Score Predicts Outcome of Second Allogeneic Hematopoietic Stem Cell Transplantation (2011) (0)
Chronic Myeloid Leukemia: Where Do We Go from Here? (2006) (0)
chronic myeloid leukemia immunotherapy in patients undergoing reduced intensity allografts for Post-transplant imatinib as a strategy to postpone the requirement for (2013) (0)
Diagnosis of leukemia, lymphoma and myeloma (2005) (0)
SURVIVAL AFTER RELAPSE IN ACUTE MYELOID LEUKÆMIA (1978) (0)
The genetic factors which affect the outcome of unrelated bone marrow transplantation (2000) (0)
O435 - NK and CTL alloreactivity due to HLA-C mismatches in BMT (1996) (0)
Contents Vol. 119, 2008 (2008) (0)
Book review (2007) (0)
A limiting dilution assay to determine the frequencies of IL-4-producing human alloreactive T helper cells (1995) (0)
Recent advances in molecular biology of chronic myeloid leukaemia: is the pathogenetic puzzle approaching solution? (1989) (0)
numbers engraftment and evidence for long-lasting reduction in stem cell allogeneic bone marrow transplantation: relationship with rate of Quantitation of mafosfamide-resistant pre-colony-forming units in (2011) (0)
reduced antigen processing, and impaired migration Dendritic cells from CML patients have altered actin organization, (2013) (0)
Cytotoxic T lymphocyte precursor frequency analysis in the selection of matched unrelated donors (1994) (0)
In CML Patients, Residual Disease In Primitive Stem/Progenitor Cells Following Allogeneic Stem Cell Transplantation Is Higher Than After Treatment With Tyrosine Kinase Inhibitors Alone, But Is Still Amenable To GVL Effects (2010) (0)
Impact of Hemochromatosis Gene (HFE) Polymorphisms and Iron Overload on Outcome of Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia (2012) (0)
Immunoresponse to Wilms Tumor antigen-1 (WT-1) in CML patients. (2000) (0)
Survival after bone-marrow transplantation. Authors' reply (2002) (0)
Blood cell autografts for patients with chronic granulocytic leukaemia in transformation (1980) (0)
leukemia cell line models MDR1 gene overexpression confers resistance to imatinib mesylate in (2013) (0)
New Directions for the Treatment of Chronic Myeloid Leukaemia (1995) (0)
The Signi ﬁ cance of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia (2013) (0)
Side-effects of the treatment of leukemias, lymphomas and myelomas (2005) (0)
Ideas of oncology (1985) (0)
Homoharringtonine in Combination with Imatinib for Patients with CML Who Have Achieved Partial or Complete Cytogenetic Responses. (2004) (0)
Targeted radiotherapy for patients with multiple myeloma: Results of pre-clinical evaluation of candidate antibodies (1999) (0)
Brief report EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors (2010) (0)
Notes and QueriesCoins for Use by Patients with Hansen's Disease (1955) (0)
Escalating-Dose HLA-mismatched donor lymphocyte infusion is safe for the treatment of 1 leukaemia relapse following alemtuzumab-based myeloablative allogeneic stem cell 2 transplantation. (2013) (0)
CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell? (2004) (0)
as Initial Therapy for Chronic Granulocytic Leukemia (2016) (0)
Death in notified cases of tuberculosis in Edinburgh: 1983-1992. (1996) (0)
Ccurrence of autoantibodies in patients developing graft versus hostdkease after allogeneicbone marrow transplant (2000) (0)
Bone marrow transplantation for chronic myeloid leukaemia. (1991) (0)
Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients (2011) (0)
Bone marrow transplantation in Asia and Australasia (1994) (0)
Philadelphia-positive mast cell differentiation of CD34+ chronic phase CML cells after long-term engraftment in NOD/SCID mice (1998) (0)
Contrasting Effects of Enhanced Sirt1 Activity in Normal and BCR-ABL1-Depedent Haematopoiesis (2012) (0)
Cml patients with advanced phase disease retain clonogenic progenitor cells which are responsive to interferon alfa and STI571 in vitro (2000) (0)
Cures in cancer (1986) (0)
intention-to-treat analysis in chronic myeloid leukemia patients Responses to second-line tyrosine kinase inhibitors are durable: an (2013) (0)
A Novel Splice Site Variant of hOCT-1 and Response to Imatinib. (2012) (0)
To the editor : Measles in bone marrow transplant recipients (2002) (0)
Examination of T cell clones derived from patients receiving DLT relapse following bone marrow transplantation (1995) (0)
cell line HL60 Immunoreactive calcitonin production by a human promyelocytic leukemia (2011) (0)
Long-Term Survival and Late Relapse in 5-Year Survivors of Allogeneic Hematopoietic-Cell Transplantation (HCT) for Chronic Myeloid Leukemia (CML) in First Chronic Phase. (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John M. Goldman?

John M. Goldman is affiliated with the following schools:

John M. Goldman's Academic­Influence.com Rankings

John M. Goldman's Degrees

Why Is John M. Goldman Influential?

John M. Goldman's Published Works

Published Works

What Schools Are Affiliated With John M. Goldman?

John M. Goldman's AcademicInfluence.com Rankings